180 Life Sciences Corp. (ATNF)
|Net Income (ttm)||-4.70M|
|Trading Day||January 22|
|Day's Range||3.38 - 4.18|
|52-Week Range||2.15 - 11.24|
Menlo Park, California--(Newsfile Corp. - January 11, 2021) - 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company with its lead ...
KBL Merger Corp. IV Announces Approval of Business Combination with 180 Life Sciences at the Special Meeting of Shareholders Held on November 5, 2020
NEW YORK, Nov. 06, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC) that previously announced an agreement to acquire ...
Last week saw continued momentum in special purpose acquisition company (SPAC) mergers, as KBL Merger (NASDAQ: KBLM), Acamar Partners Acquisition Corp. (NASDAQ: ACAM), Panacea Acquisition Corp...
NEW YORK, Oct. 23, 2020 (GLOBE NEWSWIRE) -- KBL Merger Corp. IV (NASDAQ: KBLM or the "Company"), a special purpose acquisition company (SPAC) that previously announced an agreement to acquire ...
KBL Merger Corp. IV (NASDAQ: KBLM) on Friday announced its acquisition of a new cannabis biotech company CannBioRx Life Sciences Corp.
180 Life Sciences, a clinical-stage biotechnology company, engages in the development of drug candidates in the areas of inflammatory diseases, fibrosis, and pain. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and Anti-TNF platform, which focuses on fibrosis and anti-tumor necrosis factors; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company is headquartered in Menlo Park, California... [Read more...]
|Stock Exchange |
|Ticker Symbol |